Postmenopausal women consistently have higher phosphorus levels than similarly aged men. As it is known that estradiol induces phosphaturia in rodents, we evaluated the cross-sectional association of sex hormones with serum phosphorus in 1346 community-living older men (mean age 76) of which 18% had moderate (stage 3) kidney disease. Using linear regression with serum phosphorus levels as the dependent variable, we found that for each 10 pg/ml higher total estradiol level there was a statistically significant 0.05 mg/dl lower serum phosphorus when adjusted for age, ethnicity, testosterone, sex hormone-binding globulin, calcium, estimated glomerular filtration rate, intact parathyroid hormone, 25(OH) vitamin D, bone mineral density, and alkaline phosphatase. These results were similar in individuals with or without chronic kidney disease. Serum testosterone concentrations were also statistically significantly associated with lower serum phosphorus levels. We confirmed these results in an independent sample of 2555 older men, wherein these associations were not attenuated when adjusted for fibroblast growth factor-23 levels. Hence, our study of community-living older men suggests that estradiol may directly or indirectly induce phosphaturia in humans. The mechanism responsible for the association of testosterone with serum phosphorus remains to be determined.
Postmenopausal women consistently have higher phosphorus levels than similarly aged men. As it is known that estradiol induces phosphaturia in rodents, we evaluated the cross-sectional association of sex hormones with serum phosphorus in 1346 community-living older men (mean age 76) of which 18% had moderate (stage 3) kidney disease. Using linear regression with serum phosphorus levels as the dependent variable, we found that for each 10 pg/ml higher total estradiol level there was a statistically significant 0.05 mg/dl lower serum phosphorus when adjusted for age, ethnicity, testosterone, sex hormone-binding globulin, calcium, estimated glomerular filtration rate, intact parathyroid hormone, 25(OH) vitamin D, bone mineral density, and alkaline phosphatase. These results were similar in individuals with or without chronic kidney disease. Serum testosterone concentrations were also statistically significantly associated with lower serum phosphorus levels. We confirmed these results in an independent sample of 2555 older men, wherein these associations were not attenuated when adjusted for fibroblast growth factor-23 levels. Hence, our study of community-living older men suggests that estradiol may directly or indirectly induce phosphaturia in humans. The mechanism responsible for the association of testosterone with serum phosphorus remains to be determined. Higher serum phosphorus levels are associated with cardiovascular disease and all-cause mortality, independent of traditional cardiovascular disease risk factors in communityliving populations; [1] [2] [3] associations that are evident even for serum phosphorus levels within the normal range, and among persons with normal kidney function. [1] [2] [3] Phosphorus induces vascular smooth muscle cells to calcify in vitro, 4 and higher serum levels are associated with arterial calcification 5 and stiffness 6, 7 in the general population. Thus, insights into the determinants of serum phosphorus on a population scale may identify new pathways contributing to cardiovascular disease. Yet, most demographical, dietary, and traditional cardiovascular disease risk factors are not strongly associated with serum phosphorus levels. 8 Known determinants such as severe chronic kidney disease (CKD) and primary hyperparathyroidism are relatively rare on a population level. Thus, determinants of serum phosphorus in community-living populations remain largely unknown.
Across previous studies conducted among communityliving populations, women of postmenopausal age consistently had serum phosphorus levels that are 0.15-0.30 mg/dl higher than those of men of the same age. 1, 3, [6] [7] [8] [9] [10] Treatment of parathyroidectomized and ovariectomized rats with estradiol results in a decrease in serum phosphorus levels and an increase in urinary phosphorus loss. 11 We hypothesized that estradiol might regulate renal phosphorus excretion in men, and that sex hormones may account for differences in serum phosphorus between older men and women. Studying this question in a cohort of older men avoids the confounding influences of endogenous changes in estradiol through the menopausal transition and effects of postmenopausal hormone therapy (HT). To that end, we evaluated the crosssectional association of sex hormone concentrations with serum phosphorus levels among community-living older men who participated in the Osteoporotic Fractures in Men (MrOs) study.
RESULTS
Among the 1346 study participants from the United States MrOs study (MrOs US), the mean age was 74±6 years and 91% were white. The mean total estradiol level was 22.6±8.6 pg/ml, mean total testosterone level was 406.8±171.1 ng/dl, mean serum phosphorus level was 3.2 ± 0.4 mg/dl, and mean estimated glomerular filtration rate (eGFR) was 76 ± 18 ml/min per 1.73 m 2 . A total of 238 subjects (18%) had eGFR o60 ml/min per 1.73 m 2 , and 8 subjects (0.6%) had eGFR o30 ml/min per 1.73 m 2 . Participants with higher serum phosphorus levels were more likely to have diabetes mellitus, higher serum calcium, and lower intact parathyroid hormone (PTH) levels. Men with higher phosphorus levels also had lower total estradiol and testosterone levels (Table 1) .
Total estradiol levels were inversely correlated with serum phosphorus in unadjusted analysis (r ¼ À0.17, Po0.001; Figure 1 ). In a model adjusted for age and race (Table 2 , model 1) each 10 pg/ml higher total estradiol level was associated with a 0.088 mg/dl lower serum phosphorus level. With additional adjustment for testosterone (model 2) and sex hormone-binding globulin (SHBG; model 3), about one-third of this association was attenuated, but despite this, total estradiol levels remained significantly associated with lower phosphorus levels. Further adjustment for serum calcium levels, eGFR, intact PTH, and 25(OH) vitamin D levels had little effect on the association (model 4); neither did adjustment for alkaline phosphatase and whole body bone mineral density (BMD), such that in the final adjusted model, every 10 pg/ml higher total estradiol level was associated with a 0.053 mg/dl lower serum phosphorus level (model 5). Results were similar when bioavailable estradiol levels were evaluated in place of total estradiol (Table 2) . Results were also similar among participants with or without CKD (defined as an eGFR o60 ml/min per 1.73 m 2 ). Each 10 pg/ml higher total estradiol level was associated with a 0.060 mg/dl lower serum phosphorus level in persons without CKD (95% confidence interval À0.097 to À0.022), and 0.038 mg/dl lower serum phosphorus level in persons with CKD (95% confidence interval À0.119 to 0.043).
Testosterone is the primary precursor of estradiol in men, and we observed some attenuation of the association of estradiol with serum phosphorus when the model was adjusted for testosterone levels. Therefore, we further explored the association of serum total testosterone with serum phosphorus. In unadjusted analysis, total testosterone was inversely correlated with serum phosphorus levels (À0.16, Po0.001; Figure 1 ). In age-and race-adjusted models, each 200 ng/dl higher total testosterone level was associated with 0.086 mg/dl lower serum phosphorus levels (Table 3 , model 1). Additional adjustment for estradiol weakened, but did not abolish this association (model 2). However when SHBG levels were included in models, the association for testosterone was returned to a magnitude similar to the unadjusted model (model 3). Further adjustment for serum calcium, eGFR, intact PTH, and 25(OH) vitamin D had little effect on the testosterone association (model 4); nor did adjustment for alkaline phosphatase and whole body BMD have any effect (model 5).
To provide a comparison of the relative strength of associations of various factors associated with serum phosphorus, we compared the b coefficients per s.d. increase for each continuous measure in our multivariable model. In age and race adjusted models, the strength of the association of estradiol with serum phosphorus was approximately the same as that of testosterone and natural log transformed intact PTH, and approximately twice as strong of that of serum calcium and eGFR (Table 4) .
Fibroblast growth factor (FGF)-23 is a novel phosphaturic hormone, and may be influenced by estradiol. Therefore, to investigate whether these results were reproducible in an independent sample, and to determine whether adjustment for FGF-23 levels may attenuate the associations, we repeated our main analysis in MrOs Sweden participants; a sister cohort to MrOs US participants with similar enrollment criteria and available measurements, plus availability of FGF-23 concentrations. The mean age of the 2555 MrOs Sweden participants was 76 ± 3 years, mean total estradiol was 21 ± 8 pg/ml, mean total testosterone was 450 ± 190 ng/dl, mean serum phosphorus was 3.3 ± 0.5 mg/dl, and mean eGFR was 72 ± 20 ml/min per 1.73 m 2 (697 [27%] had eGFR o60). FGF-23 levels were right skewed with a median level of . Line within boxes shows median level, borders of boxes reflect the twenty-fifth and twenty-seventh percentile of the distribution, and border of error bars reflect the tenth and ninetieth percentile of the distribution. Total estradiol quartiles (in pg/ml) were o17.2 for quartile 1, 17.2-21.6 for quartile 2, 21.7-27.0 for quartile 3, and 427.0 for quartile 4. Total testosterone quartiles (in ng/dl) were o300 for quartile 1, 300-387 for quartile 2, 388-488 for quartile 3, and 4448 for quartile 4. 44 pg/ml (interquartile range 33-58 pg/ml). Other characteristics of MrOs Sweden participants have been described in detail elsewhere. 12 The adjusted associations of estradiol and testosterone levels with serum phosphorus levels in MrOs Sweden participants were in the same direction and of similar strength to those in MrOs US participants. Further adjustment for FGF-23 levels did not materially alter the sex hormone-serum phosphorus associations (Table 5) .
DISCUSSION
We have shown that higher serum estradiol and testosterone levels are each independently associated with lower serum phosphorus levels in community-living older men. These associations were reproducible in an independent cohort of older men in Sweden and were not explained by one another, SHBG levels, kidney function, intact PTH, 25(OH) vitamin D, or FGF-23 levels. In conjunction with the previous reports, this study suggests that estradiol may have phosphaturic properties in humans. Little is known about the effects of testosterone on phosphorus homeostasis. The inverse correlation of testosterone and phosphorus levels reported in this study may reflect enhanced deposition of phosphorus into bone, reduced bone resorption, or previously unrecognized effects on gastrointestinal absorption or renal excretion of phosphorus.
Correlates of phosphorus levels in the general population were recently evaluated in the Third National Health and Nutrition Examination Survey (NHANES III). 7 Dietary The renal regulation of phosphorus is principally achieved through the sodium phosphate co-transporter type IIa (NaPi-IIa) in the proximal convoluted tubule. [13] [14] [15] Recently, Faroqui et al. 11 reported that treatment of parathyroidectomized and ovariectomized rats with estradiol decreased NaPi-IIa mRNA and protein levels, resulting in lower serum phosphorus levels and enhanced urinary phosphorus loss. To our knowledge, no previous study has evaluated the association of endogenous serum estradiol and phosphorus levels in humans, but existing data support a similar effect. In an observational study among over 4500 community-living Italians with a wide age spectrum, men had a modest and linear decrease in serum phosphorus level with advancing age. Women followed a similar trajectory until age 45-54, when there was an abrupt increase in serum phosphorus levels and commensurate decrease in urinary phosphorus loss, perhaps resulting from decreased endogenous estradiol during the menopausal transition. 9 In the Atherosclerosis Risk in Communities (ARIC) study, women taking HT had significantly lower serum phosphorus levels compared with women not taking HT. 10 Observational studies and small randomized clinical trials have evaluated urine phosphorus excretion with HT therapy. HT treatment resulted in lower serum phosphorus levels and greater phosphaturia compared with pre-treatment levels or to the placebo arm. [16] [17] [18] [19] Although estradiol has skeletal and other non-renal effects that could affect phosphorus homeostasis, our leading hypothesis is that the association reported in this study resulted primarily from estradiol increasing urinary phosphorus excretion among older men. This hypothesis is supported further by the observation that inverse correlation of estradiol and phosphorus was essentially unaltered with adjustment for alkaline phosphatase and BMD.
While evidence provided in this study and elsewhere support the hypothesis that estradiol decreases NaPi-IIa mRNA and protein levels, and induces phosphaturia, the cellular mechanisms remain uncertain. Estrogen receptors (ERs) are expressed in the proximal tubule of the rat kidney, 20 so a direct effect is possible. The majority of the estrogen response is mediated through two ERs, ERa and ERb. In rats, Faroqui et al.
11 observed decreased NaPi-IIa levels and phosphaturia in response to estradiol in vivo, however, this effect was not blunted with a specific inhibitor of ERa. No change in klotho levels (a key cofactor for FGF-23 binding) was observed with estradiol therapy in this study. Using a 7/8 nephrectomy CKD model in rats, Carrillo-Lopez et al. 21 recently showed that estradiol increased serum FGF-23 levels in vivo, and increased FGF-23 mRNA and protein levels in a rat-derived osteoblast cell line in vitro. Because FGF-23 decreases NaPi-IIa levels in the proximal tubule and induces phosphaturia, 22 this finding suggests that estradiol may induce phosphaturia indirectly, through upregulation of FGF-23. In our study, among the subset of 2555 MrOs Sweden participants, statistical adjustment for FGF-23 levels did not materially alter the associations of estradiol or testosterone with serum phosphorus levels, arguing against this hypothesis. Our observational study cannot definitively elucidate the biological pathways responsible for these associations. Possibilities that a direct effect of estradiol may be mediated through ERb or other estrogen ligands have not yet been investigated, to our knowledge.
Studies evaluating the effect of testosterone on renal phosphorus homeostasis are sparse, conflicting, and often confounded by concomitant changes in estradiol. Ralston et al. evaluated treatment with estradiol versus estradiol þ testosterone for 6 months in 32 young surgically menopausal women. Both groups had decreases in serum phosphorus and increases in phosphaturia of similar magnitude compared with pre-treatment baseline. 23 Treatment of healthy middle-aged men with goserelin decreases both serum testosterone and estradiol, and concomitantly increases serum phosphorus levels and decreases phosphaturia. 24 In experimental animals, some have reported effects in the opposite direction to those observed in this study. Orchiectomized male rats show lower serum phosphorus levels compared with non-orchiectomized controls, and testosterone treatment restored serum phosphorus levels. 25 Several possibilities may account for the inverse correlation between total testosterone with serum phosphorus levels in our study. First, while adjustment for whole body BMD had little effect on the association in our study, testosterone increases bone formation and reduces bone resorption, which might affect serum phosphorus levels. Second, testosterone is the predominant precursor of estradiol in men. 26, 27 However, it appears unlikely that the association of testosterone with serum phosphorus is mediated through estradiol because statistical adjustment for estradiol had little effect on the association of testosterone with phosphorus in both the MrOs US and MrOs Sweden cohorts. Last, it remains possible that testosterone may have unrecognized effects on renal or gastrointestinal phosphorus metabolism.
Previous studies consistently show phosphorus levels that are approximately 0.15-0.30 mg/dl higher in older women compared with similar aged men. 1, 3, [6] [7] [8] [9] [10] In this study, we report that each 10 pg/ml higher estradiol and 200 ng/dl higher testosterone were independently associated with lower serum phosphorus levels, (approximately 0.05 and 0.08 mg/ dl, respectively in MrOs US participants) in men. Although this effect size may seem clinically insignificant, interpretation requires recognition that older men have serum estradiol levels that are approximately fourfold higher (B15 pg/ml greater), and serum testosterone levels that are approximately 20-fold higher (B285 ng/dl) than postmenopausal women. 28 On the basis of the strengths of the observed associations, differences in estradiol would be expected to account for Kidney International (2010) 78, 415-422 approximately 0.09 mg/dl higher serum phosphorus level, and differences in testosterone would account for an additional 0.12 mg/dl higher phosphorus level in women compared with men. Collectively, this magnitude of difference in serum phosphorus compares favorably to differences in phosphorus levels between men and women reported in previous studies. Future studies of both sexes and concurrent measures of estradiol, testosterone, serum and urine phosphorus levels are required to determine whether differences in sex hormones entirely account for the sex differences in serum phosphorus levels.
Strengths of this study include its relatively large sample size, community living and geographically diverse setting, and availability of demographical, laboratory, and BMD measurements in all participants. The similar design and measurements in MrOs Sweden participants allowed us to test reproducibility and evaluate potential mediation through FGF-23. All phosphorus measurements were made in fasting morning specimens, decreasing influences of diurnal variation. However, the study also has important limitations. We lacked urinary phosphorus measurements, participants were all older, most were Caucasian, and few had CKD. Results may differ in younger persons, other race ethnicities or in moderate to advanced CKD. The cross-sectional study design did not allow evaluation of temporality.
We conclude that higher serum estradiol levels and testosterone levels are each independently associated with lower serum phosphorus levels in community-living older men. These associations were not attenuated with adjustment for FGF-23 levels. In the context of previous studies, these data suggest that estradiol may directly or indirectly induce phosphaturia in humans. The mechanism responsible for the association of testosterone with serum phosphorus is less certain, but may reflect either bone or previously unrecognized renal or gastrointestinal effects, or conversion to estradiol. Future studies should evaluate whether differences in sex hormones may explain why higher phosphorus levels are consistently observed in older women compared with men.
MATERIALS AND METHODS Study participants
MrOs US. The primary analysis for this study evaluated participants in the MrOs US study; an observational cohort study designed to evaluate risk factors for fractures in older men. 29, 30 Between March 2000 and April 2002, 5995 men aged X65 years were recruited from Birmingham, Alabama; Minneapolis, Minnesota; Palo Alto, California; Pittsburgh, Pennsylvania; Portland, Oregon; and San Diego, California. Inclusion required ability to walk without the assistance of another person; absence of bilateral hip replacements; ability to provide self-reported data and informed consent; planned residence near a field center site for the duration of the study; and absence of medical conditions judged by the investigator to result in imminent death. Institutional review boards at each center approved the study.
From the cohort, random number generators were used to select 1602 men for measurement of sex hormones. Among these, we excluded 17 (1%) with missing serum estradiol measurement, 94 (6%) with missing serum phosphorus measurements, and 145 (9%) with missing covariate data, providing a final analytical sample of 1346 subjects for the present analyses.
MrOs Sweden. FGF-23 measurements were considered a key candidate mediator of the association of sex hormones with serum phosphorus, and were not available in MrOs US participants. Therefore, to confirm our findings in an independent cohort, and to evaluate whether FGF-23 levels attenuated the associations, we performed a secondary analysis in MrOs Sweden participants-a sister study to MrOs US participants with a similar design. Study participants were recruited from three Swedish cities (Malmo, Goteborg, and Uppsala), identified using national population registers. Inclusion required male sex, age 69-80 years, and ability to walk without assistance. Informed consent was obtained from all study participants.
Among the 3014 MrOs Sweden participants, 375 were excluded for missing serum estradiol or testosterone measurements, 25 were excluded for missing serum phosphorus measurements, 30 were excluded for missing FGF-23 measurements, and 29 were excluded for other missing covariates, resulting in a study sample of 2555 participants (85%) for this study.
Measurements
Sex hormones. All blood measurements were performed on venous samples obtained after an overnight fast. Total serum estradiol and testosterone were measured using a combined tandem mass spectrometry (Taylor Technology, Princeton, NJ, USA). The range of detection for estradiol and testosterone were 0.625-80 and 25-3200 pg/ml, and the intra-assay and inter-assay coefficients of variation (CV) were o7 and o11%, respectively. SHBG was measured using an Immulite Analyzer with chemiluminescent substrate (Diagnostic Products Corp., Los Angeles, CA, USA). The standard curve ranged from 0.2 to 180 nm/l and CVs were o6%. All sex hormone and SHBG values were above the respective assay sensitivities. Serum albumin levels were analyzed using a Roche COBAS Integra 800 automated analyzer (Roche Diagnostics Corp., Indianapolis, IN, USA), with a detectable range from 0.2 to 6.0 g/dl, and with CV's o2%. These measurements were combined in the Sodergard equation 31 to calculate bioavailable estradiol and testosterone levels. Constants used in calculations were 3.14 Â 10 8 l/ mol for estradiol to SHBG, 4.21 Â 10 4 l/mol for estradiol to albumin, 5.97 Â 10 8 l/mol for testosterone to SHBG, and 4.06 Â 10 4 l/mol for testosterone to albumin. 32 In MrOs Sweden participants, sex hormones were also measured by mass spectroscopy using a HP5973 quadrupole mass spectrometer as described elsewhere. 33 For total estradiol, the intra-assay CV was 1.5% and inter-assay CV was 2.7%, and for total testosterone the intra-assay CV was 2.9% and inter-assay CV was 3.4%.
Serum phosphorus. In MrOs US participants, serum phosphorus measurements were made from morning fasting blood specimens using a standard clinical automated analyzer (Roche COBAS Integra 800, Roche Diagnostics) at a central laboratory at the University of Oregon Health Sciences Center. The range of detection was 0.3-20.0 mg/dl, all values were within the assay limits, and CV's were o3%. In a similar manner, serum phosphorus measurements were made by a standard clinical chemistry analyzer in the Department of Clinical Chemistry at the Uppsala University Hospital in MrOs Sweden, as described elsewhere. 34 Other measurements. Standardized questionnaires provided information on the participants' age, race, and history of hypertension and smoking. Prevalent diabetes was defined by fasting glucose 4126 mg/dl, use of oral hypoglycemic medications or insulin, or self-report. Dietary intake of fat, calories, calcium, and phosphorus were assessed by a modified Block Dietary Data Systems questionnaire (Block Dietary Data Systems, Berkeley, CA, USA). Medications were recorded by trained study personnel at the baseline clinic visit, and were matched to their ingredients based on the Iowa Drug Information Service (IDIS) Drug Vocabulary (College of Pharmacy, University of Iowa, Iowa City, IA, USA). 35 Height and weight were measured with subjects wearing light clothes and no shoes, and body mass index was calculated (weight (kg)/height (m)
2 ). Systolic blood pressure was measured twice at the right brachial artery using a standard sphygmomanometer and an 8-MHz Doppler probe after a 5-min rest.
Serum calcium, creatinine, alkaline phosphatase, high-density lipoprotein, total cholesterol, and triglyceride assays were measured using a Roche COBAS Integra 800 automated analyzer, and lowdensity lipoprotein was calculated using the Friedewald equation. 36 eGFR was calculated using the modified four-variable Modification of Diet in Renal Disease equation. 37, 38 25(OH) vitamin D2 and D3 were measured using liquid chromatography-mass spectrometry, with deuterated stable isotope 25(OH) vitamin D3 used as the internal standard. The CVs were o5.0%. The minimum detectable limit for vitamin D2 is o4 ng/ml and for vitamin D3 is o2 ng/ml. The sum of vitamin D2 and D3 were used for 25(OH) vitamin D levels in analyses. Total intact PTH was measured using the Immunoradiometric Assay 3KG600 (Scantibodies Laboratories Inc., Santee, CA, USA) with CVs o8.5%.
Whole body BMD was measured using dual energy X-ray absorptiometry (Hologic, Bedford, MA, USA). A central quality control lab, certification of dual energy X-ray absorptiometry operators, and standardized procedures for scanning were used to insure reproducibility of dual energy X-ray absorptiometry measurements across field centers. The inter-clinic CVs were 0.6% for the spine and 0.9% for the hip.
Finally, in MrOs Sweden participants, intact FGF-23 levels were measured using enzyme-linked immunosorbent assay according to the manufacturer's protocol (Kainos Laboratories International, Tokyo, Japan), as described elsewhere. 34, 39 The two-site enzymelinked immunosorbent assay has previously been shown to recognize only biologically active FGF-23, and not inactive C-terminal fragments.
Statistical analysis
We used the MrOs US participants samples for the primary analysis for this study. Baseline differences in demographical and clinical variables of the MrOs US participants samples were compared across phosphorus categories using analysis of variance or Kruskal-Wallis test for continuous variables, and Chi-squared test for categorical variables. Graphical methods showed an approximate Gaussian distribution for serum phosphorus levels, and a linear relationship between estradiol and phosphorus levels. We used multivariate linear regression to evaluate the association of total estradiol as the primary predictor variable of interest, and with serum phosphorus levels as the dependent variable. An initial model was unadjusted. Model 1 adjusted for age and race, model 2 additionally adjusted for testosterone, and model 3 additionally adjusted for SHBG. Model 4 adjusted for other variables selected a priori based on hypothesized influences on serum phosphorus levels (eGFR, intact PTH, calcium, and 25(OH) vitamin D). A final model additionally adjusted for whole body BMD and serum alkaline phosphatase levels, as we hypothesized that the association of estradiol with serum phosphorus would be mediated through changes in urinary phosphorus regulation, and therefore, would remain independent of BMD and markers of bone turnover. Next, we evaluated whether results were similar in subjects with or without CKD (defined as eGFR o60 ml/min per 1.73 m 2 ). These sequences of models were repeated evaluating serum total testosterone as the predictor variable of interest. In companion analyses, we also evaluated the associations of bioavailable estradiol and testosterone levels with serum phosphorus levels. Next, we compared the relative strength of association of estradiol and testosterone with serum phosphorous to the other variables used in the multivariable models. To facilitate comparison, each was evaluated as per s.d. change. Skewed variables were natural-log transformed.
In companion analyses, we replicated the multivariable models evaluating the association of total estradiol and testosterone with phosphorus in MrOs Sweden participants. Models were adjusted for model 4 variables, as described earlier, with two exceptions. All MrOs Sweden participants were Caucasian, so the race term was omitted. MrOs Sweden participants came from three Swedish cities, so a term for city was included to account for potential regional differences in study participant characteristics.
We used STATA version 9.2 and 10 SE (StataCorp LP, College Station, TX, USA), and two-tailed Po0.05 were considered statistically significant for all analyses including interaction terms.
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